The 5 analysts offering 12-month price forecasts for OncoCyte Corp have a median target of 7.00, with a high estimate of 11.00 and a low estimate of 6.00. The median estimate represents a +209.73% increase from the last price of 2.26.
The current consensus among 5 polled investment analysts is to Buy stock in OncoCyte Corp. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.12
Reporting Date Apr 04
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.